FAP and central nervous system cancer: There was no statistically significant disparity observed in FAP levels between grade 2 and grade 3 gliomas within the IDH-mutant glioma cohort(Fig. 1IIIb; P = 0.8895), whereas in the cohort of IDH-wildtype glioma patients, a elevation in serum FAP levels was observed specifically among grade 4 gliomas, but this differecne did not reach statistical significance (Fig. 1 IIIc; P1 = 0.3865, P2 = 0.2415, P3 = 0.0993).